Gilead Sciences Inc (0QYQ)

London
Currency in USD
106.31
+0.90(+0.85%)
Closed
0QYQ Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
Trading near 52-week High
Fair Value
Day's Range
105.23107.05
52 wk Range
62.19107.05
Key Statistics
Edit
Bid/Ask
101.00 / 111.62
Prev. Close
105.41
Open
105.13
Day's Range
105.23-107.05
52 wk Range
62.19-107.05
Volume
4.38K
Average Volume (3m)
57.74K
1-Year Change
46.59%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0QYQ Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Gilead Sciences Inc Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Employees
18000

Compare 0QYQ to Peers and Sector

Metrics to compare
0QYQ
Peers
Sector
Relationship
P/E Ratio
273.3x−1.4x−0.7x
PEG Ratio
−2.97−0.010.00
Price/Book
6.8x0.5x2.6x
Price / LTM Sales
4.6x5.1x3.1x
Upside (Analyst Target)
-305.7%49.4%
Fair Value Upside
Unlock16.7%8.9%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.385
Dividend Yield
3.02%
Industry Median 2.52%
Annualized payout
3.16
Paid quarterly
5-Years Growth
+4.10%
Growth Streak

Earnings

Latest Release
Feb 11, 2025
EPS / Forecast
1.90 / 1.71
Revenue / Forecast
7.57B / 7.16B
EPS Revisions
Last 90 days

People Also Watch

114.26
FTNT
0.00%
774.11
KLAC
+2.09%
63.64
MCHP
+9.99%
363.81
LULU
-2.32%
196.16
IQV
+1.56%

FAQ

What Is the Gilead (0QYQ) Stock Price Today?

The Gilead stock price today is 106.31

What Stock Exchange Does Gilead Trade On?

Gilead is listed and trades on the London stock exchange.

What Is the Stock Symbol for Gilead?

The stock symbol for Gilead is "0QYQ."

Does Gilead Pay Dividends? What’s The Current Dividend Yield?

The Gilead Sciences Inc dividend yield is 3.01%.

What Is the Gilead Market Cap?

As of today, Gilead market cap is 133.49B.

What is Gilead Earnings Per Share?

The Gilead EPS is 0.385.

What Is the Next Gilead Earnings Date?

Gilead will release its next earnings report on Apr 23, 2025.

From a Technical Analysis Perspective, Is 0QYQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.